Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1

被引:63
作者
Bouhlal, H
Hocini, H
Quillent-Grégoire, C
Donkova, V
Rose, S
Amara, A
Longhi, R
Haeffner-Cavaillon, N
Beretta, A
Kaveri, SV
Kazatchkine, MD
机构
[1] Univ Paris 06, Hop Broussais, INSERM Unite 430, F-75674 Paris 14, France
[2] INSERM Unite 2 430, F-75674 Paris 14, France
[3] Hop St Joseph, CIRBS, Paris, France
[4] Inst Pasteur, Paris, France
[5] Fdn Ctr S Raffaele Monte Tabor, Milan, Italy
[6] CNR Lab, Milan, Italy
关键词
D O I
10.4049/jimmunol.166.12.7606
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the present study, we demonstrate that normal human IgG for therapeutic use (i.v. Ig) contains natural Abs directed against the CCR5 coreceptor for HIV-1. Abs to CCR5 were isolated from i.v. Ig using an affinity matrix consisting of a synthetic peptide corresponding to the N-terminus of CCR5 coupled to Sepharose. Natural anti-CCR5 Abs inhibited the binding of RANTES to macrophages, demonstrating their interaction with the coreceptor of R5-tropic HIV-1. Affinity-purified anti-CCR5 Ig further inhibited infection of lymphocytes and monocytes/macrophages with primary and laboratory-adapted strains of HIV-1, but did not inhibit infection with X4-tropic HIV. Our results suggest that anti-CCR5 Abs from healthy immunocompetent donors may be suitable for development of novel passive immunotherapy regimens in specific clinical settings in HIV infection.
引用
收藏
页码:7606 / 7611
页数:6
相关论文
共 32 条
[1]   HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication [J].
Amara, A ;
LeGall, S ;
Schwartz, O ;
Salamero, J ;
Montes, M ;
Loetscher, P ;
Baggiolini, M ;
Virelizier, JL ;
ArenzanaSeisdedos, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :139-146
[2]  
AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154
[3]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[4]   High-avidity autoantibodies to cytokines [J].
Bendtzen, K ;
Hansen, MB ;
Ross, C ;
Svenson, M .
IMMUNOLOGY TODAY, 1998, 19 (05) :209-211
[5]   Chemokines and HIV-1 second receptors: The therapeutic connection [J].
Cairns, JS ;
D'Souza, MP .
NATURE MEDICINE, 1998, 4 (05) :563-568
[6]   Change in coreceptor use correlates with disease progression in HIV-1-infected individuals [J].
Connor, RI ;
Sheridan, KE ;
Ceradini, D ;
Choe, S ;
Landau, NR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :621-628
[7]   Natural autoantibodies [J].
Coutinho, A ;
Kazatchkine, MD ;
Avrameas, S .
CURRENT OPINION IN IMMUNOLOGY, 1995, 7 (06) :812-818
[8]   Identification of a major co-receptor for primary isolates of HIV-1 [J].
Deng, HK ;
Liu, R ;
Ellmeier, W ;
Choe, S ;
Unutmaz, D ;
Burkhart, M ;
DiMarzio, P ;
Marmon, S ;
Sutton, RE ;
Hill, CM ;
Davis, CB ;
Peiper, SC ;
Schall, TJ ;
Littman, DR ;
Landau, NR .
NATURE, 1996, 381 (6584) :661-666
[9]   The CCR5 receptor acts as an alloantigen in CCR5Δ32 homozygous individuals:: Identification of chemokine- and HIV-1-blocking human antibodies [J].
Ditzel, HJ ;
Rosenkilde, MM ;
Garred, P ;
Wang, M ;
Koefoed, K ;
Pedersen, C ;
Burton, DR ;
Schwartz, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5241-5245
[10]   SOLID-PHASE PEPTIDE-SYNTHESIS UTILIZING 9-FLUORENYLMETHOXYCARBONYL AMINO-ACIDS [J].
FIELDS, GB ;
NOBLE, RL .
INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, 1990, 35 (03) :161-214